Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care

被引:58
作者
Honkoop, Persijn J. [1 ,2 ]
Loijmans, Rik J. B. [3 ]
Termeer, Evelien H. [5 ]
Snoeck-Stroband, Jiska B. [1 ]
van den Hout, Wilbert B. [1 ]
Bakker, Moira J. [1 ]
Assendelft, Willem J. J. [2 ,5 ]
ter Riet, Gerben [3 ]
Sterk, Peter J. [4 ]
Schermer, Tjard R. J. [5 ]
Sont, Jacob K. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, NL-2300 RC Leiden, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1105 AZ Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands
[5] Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, Nijmegen, Netherlands
关键词
Quality of life; fraction of exhaled nitric oxide; asthma exacerbations; asthma control; cost-effectiveness; online decision support; QUALITY-OF-LIFE; INHALED CORTICOSTEROIDS; ECONOMIC-EVALUATION; SAMPLE-SIZE; MANAGEMENT; VALIDATION; COST; STANDARDIZATION; EXACERBATIONS; QUESTIONNAIRE;
D O I
10.1016/j.jaci.2014.07.016
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Aiming at partly controlled asthma (PCa) instead of controlled asthma (Ca) might decrease asthma medication use. Biomarkers, such as the fraction of exhaled nitric oxide (FENO), allow further tailoring of treatment. Objective: We sought to assess the cost-effectiveness and clinical effectiveness of pursuing PCa, Ca, or FENO-driven controlled asthma (FCa). Methods: In a nonblind, pragmatic, cluster-randomized trial in primary care, adults (18-50 years of age) with a doctor's diagnosis of asthma who were prescribed inhaled corticosteroids were allocated to one of 3 treatment strategies: (1) aiming at PCa (Asthma Control Questionnaire [ACQ] score < 1.50); (2) aiming at Ca (ACQ score < 0.75); and (3) aiming at FCa (ACQ score < 0.75 and FENO value < 25 ppb). During 12 months' follow-up, treatment was adjusted every 3 months by using an online decision support tool. Outcomes were incremental cost per quality-adjusted life year gained, asthma control (ACQ score), quality of life (Asthma Quality of Life Questionnaire score), asthma medication use, and severe exacerbation rate. Results: Six hundred eleven participants were allocated to the PCa (n = 219), Ca (n = 203), or FCa (n = 189) strategies. The FCa strategy improved asthma control compared with the PCa strategy (P <.02). There were no differences in quality of life (P >=.36). Asthma medication use was significantly lower for the PCa and FCa strategies compared with the Ca strategy (medication costs: PCa, $452; Ca, $551; and FCa, $456; P <=.04). The FCa strategy had the highest probability of cost-effectiveness at a willingness to pay of $50,000/quality-adjusted life year (86%; PCa, 2%; Ca, 12%). There were no differences in severe exacerbation rate. Conclusion: A symptom-plus FENO-driven strategy reduces asthma medication use while sustaining asthma control and quality of life and is the preferred strategy for adult asthmatic patients in primary care.
引用
收藏
页码:682 / U158
页数:18
相关论文
共 50 条
[1]   Counting, analysing and reporting exacerbations of COPD in randomised controlled trials [J].
Aaron, S. D. ;
Fergusson, D. ;
Marks, G. B. ;
Suissa, S. ;
Vandemheen, K. L. ;
Doucette, S. ;
Maltais, F. ;
Bourbeau, J. F. ;
Goldstein, R. S. ;
Balter, M. ;
O'Donnell, D. ;
FitzGerald, M. .
THORAX, 2008, 63 (02) :122-128
[2]   The Cost of Persistent Asthma in Europe: An International Population-Based Study in Adults [J].
Accordini, Simone ;
Corsico, Angelo G. ;
Braggion, Marco ;
Gerbase, Margaret W. ;
Gislason, David ;
Gulsvik, Amund ;
Heinrich, Joachim ;
Janson, Christer ;
Jarvis, Deborah ;
Jogi, Rain ;
Pin, Isabelle ;
Schoefer, Yvonne ;
Bugiani, Massimiliano ;
Cazzoletti, Lucia ;
Cerveri, Isa ;
Marcon, Alessandro ;
de Marco, Roberto .
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2013, 160 (01) :93-101
[3]   ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005 [J].
American Thoracic Society ;
European Respiratory Society .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) :912-930
[4]  
[Anonymous], 1987, MULTIPLE IMPUTATION
[5]  
[Anonymous], 2008, BRIT GUID MAN ASTHM
[6]  
Asthma UK, 2013, ANN REP ACC 2013
[7]   Can guideline-defined asthma control be achieved? The gaining optimal asthma control study [J].
Bateman, ED ;
Boushey, HA ;
Bousquet, J ;
Busse, WW ;
Clark, TJH ;
Pauwels, RA ;
Pedersen, SE .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (08) :836-844
[8]   Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma The BASALT Randomized Controlled Trial [J].
Calhoun, William J. ;
Ameredes, Bill T. ;
King, Tonya S. ;
Icitovic, Nikolina ;
Bleecker, Eugene R. ;
Castro, Mario ;
Cherniack, Reuben M. ;
Chinchilli, Vernon M. ;
Craig, Timothy ;
Denlinger, Loren ;
DiMango, Emily A. ;
Engle, Linda L. ;
Fahy, John V. ;
Grant, J. Andrew ;
Israel, Elliot ;
Jarjour, Nizar ;
Kazani, Shamsah D. ;
Kraft, Monica ;
Kunselman, Susan J. ;
Lazarus, Stephen C. ;
Lemanske, Robert F., Jr. ;
Lugogo, Njira ;
Martin, Richard J. ;
Meyers, Deborah A. ;
Moore, Wendy C. ;
Pascual, Rodolfo ;
Peters, Stephen P. ;
Ramsdell, Joe ;
Sorkness, Christine A. ;
Sutherland, E. Rand ;
Szefler, Stanley J. ;
Wasserman, Stephen I. ;
Walter, Michael J. ;
Wechsler, Michael E. ;
Boushey, Homer A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (10) :987-997
[9]   Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma [J].
Campbell, Jonathan D. ;
Blough, David K. ;
Sullivan, Sean D. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2008, 101 (05) :474-481
[10]   Sample size calculator for cluster randomized trials [J].
Campbell, MK ;
Thomson, S ;
Ramsay, CR ;
MacLennan, GS ;
Grimshaw, JM .
COMPUTERS IN BIOLOGY AND MEDICINE, 2004, 34 (02) :113-125